<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">transmed</journal-id><journal-title-group><journal-title xml:lang="ru">Трансляционная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Translational Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-4495</issn><issn pub-type="epub">2410-5155</issn><publisher><publisher-name>Almazov National Medical Research Centre, Saint Petersburg, Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2311-4495-2022-9-3-59-69</article-id><article-id custom-type="elpub" pub-id-type="custom">transmed-711</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CARDIOVASCULAR MEDICINE</subject></subj-group></article-categories><title-group><article-title>Исследование циркулирующих внеклеточных везикул различного клеточного происхождения и их активности у пациентов с посттромбоэмболическим синдромом</article-title><trans-title-group xml:lang="en"><trans-title>Evaluation of the profile of circulating extracellular vesicles of different cell origin and their activity in patients with postthromboembolic syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Золотова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zolotova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Золотова Екатерина Алексеевна - аспирант кафедры лабораторной медицины и генетики.</p><p>Ул. Аккуратова, д. 2, Санкт-Петербург, 197341</p></bio><bio xml:lang="en"><p>Ekaterina A. Zolotova - PhD student of Department of Laboratory Medicine and Genetics.</p><p>Akkuratova str., 2, Saint Petersburg,197341</p></bio><email xlink:type="simple">katerinazolotova1@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Симакова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Simakova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Симакова Мария Александровна - кандидат медицинских наук, старший научный сотрудник научно-исследовательской лаборатории кардиомиопатий, руководитель научно-исследовательской группы по кардиоонкологии научно-исследовательского центра персонализированной медицины.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Maria A. Simakova - MD, PhD, Senior Researcher, Noncoronary Heart Disease Department, Head of Research Group of Cardio-oncology, Research Centre of Personolized Oncology, World-Class Research Centre for Personalized Medicine.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мельничникова</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Melnichnikova</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мельничникова Ольга Сергеевна - кандидат медицинских наук, старший научный сотрудник научно-исследовательской группы по кардиоонкологии научно-исследовательского центра персонализированной медицины.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Olga S. Melnichnikova - MD, PhD, Senior Researcher, Research Group of Cardio-Oncology, World-Class Research Centre for Personalized Medicine.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сироткина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sirotkina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сироткина Ольга Васильевна - доктор биологических наук, профессор кафедры лабораторной медицины и генетики ФГБУ «НМИЦ им. В. А. Алмазова; ведущий научный сотрудник лаборатории молекулярной генетики человека Петербургского института ядерной физики им. Б. П. Константинова НИЦ Курчатовский институт; старший научный сотрудник отдела молекулярно-генетических и нанобиологических технологий Первого Санкт-Петербургского ГМУ им. акад. И. П. Павлова.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Olga V. Sirotkina - MD, PhD, DSc, professor of Department of Laboratory Medicine and Genetics, Almazov National MRC, senior researcher, Petersburg Nuclear Physics Institute named by B.P. Konstantinov of NRC «Kurchatov Institute»; senior researcher, Pavlov First Saint-Petersburg SMU.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жиленкова</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhilenkova</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Жиленкова Юлия Исмаиловна - кандидат медицинских наук, доцент кафедры лабораторной медицины и генетики.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Yulia I. Zhilenkova - MD, PhD, Associate Professor of Department of Laboratory Medicine and Genetics.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеева</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseeva</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Моисеева Ольга Михайловна - доктор медицинских наук, профессор, заведующий научно-исследовательским отделом некоронарогенных заболеваний сердца.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Olga M. Moiseeva - MD, PhD, DSc, Professor, Head, Noncoronary Heart Disease Department.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вавилова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vavilova</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вавилова Татьяна Владимировна - доктор медицинских наук, профессор, заведующий кафедрой лабораторной медицины и генетикию.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Tatiana V. Vavilova - MD, PhD, DSс, Professor, Head of Department of Laboratory Medicine and Genetics.</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение Национальный медицинский исследовательский центр имени  В. А. Алмазова Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение Национальный медицинский исследовательский центр имени  В. А. Алмазова Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное учреждение Петербургский институт ядерной физики имени Б.П. Константинова, Национальный исследовательский центра Курчатовский институт; Федеральное государственное бюджетное образовательное учреждение высшего образования Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre; Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre Kurchatov Institute; Academician I.P. Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>28</day><month>09</month><year>2022</year></pub-date><volume>9</volume><issue>3</issue><fpage>59</fpage><lpage>69</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Золотова Е.А., Симакова М.А., Мельничникова О.С., Сироткина О.В., Жиленкова Ю.И., Моисеева О.М., Вавилова Т.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Золотова Е.А., Симакова М.А., Мельничникова О.С., Сироткина О.В., Жиленкова Ю.И., Моисеева О.М., Вавилова Т.В.</copyright-holder><copyright-holder xml:lang="en">Zolotova E.A., Simakova M.A., Melnichnikova O.S., Sirotkina O.V., Zhilenkova Y.I., Moiseeva O.M., Vavilova T.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://transmed.almazovcentre.ru/jour/article/view/711">https://transmed.almazovcentre.ru/jour/article/view/711</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Хроническая тромбоэмболическая легочная гипертензия (ХТЭЛГ) и хроническая тромбоэмболическая болезнь (ХТЭБ) — проявления посттромбоэмболического синдрома у пациентов, перенесших тромбоэмболию легочной артерии (ТЭЛА). Было показано, что внеклеточные везикулы (ВВ) различного клеточного происхождения участвуют в патогенезе данных заболеваний благодаря активации системы гемостаза.</p></sec><sec><title>Цель</title><p>Цель. Оценка относительного количества ВВ и их коагуляционной активности с помощью теста генерации тромбина у пациентов с посттромбоэмболическим синдромом.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включен 21 пациент: группа ХТЭБ (n = 7) (ДЛА &lt; 25 мм рт. ст.) и группа ХТЭЛГ (n = 14) с прекапиллярной ЛГ. Группа сравнения — доноры (n = 11) без сердечно-сосудистых и тромбоэмболических заболеваний в анамнезе. ВВ выделяли набором Exo-FACS и анализировали методом проточной цитометрии с использованием флуоресцентно меченных антител к клеточным маркерам. Оценка активности микрочастиц проводилась в тесте генерации тромбина с использованием триггерного реактива без добавления ТФ с помощью планшетного флюориметра.</p></sec><sec><title>Результаты</title><p>Результаты. У пациентов с ХТЛГ и ХТЭБ относительное содержание внеклеточных везикул тромбоцитарного и эндотелиального происхождения выше по сравнению с группой контроля. Уровень тромбоцитарных внеклеточных везикул коррелирует с уровнями СРБ и D-димера. В тесте генерации тромбина у пациентов с ХТЭЛГ значимо увеличено LT и ttPeak относительно контроля.</p></sec><sec><title>Выводы</title><p>Выводы. Повышение уровня ВВ тромбоцитарного и эндотелиального происхождения у пациентов с ХТЭЛГ и ХТЭБ свидетельствует о вкладе микровезикуля</p><p>ции в формирование посттромбоэмболического синдрома. Понижение активности генерации тромбина под действием ТФ-ВВ возможна в результате эффекта потребления ТФ при эндотелиальной дисфункции либо при длительной активации прокоагулянтных путей.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Chronic thromboembolic pulmonary hypertension (CTEPH) and chronic thromboembolic disease (CTEP) are manifestations of post-thromboembolic syndrome in patients with pulmonary embolism. Extracellular vesicles (EVs) are involved in the pathogenesis of these diseases due to the activation of the hemostasis system.</p></sec><sec><title>Objective</title><p>Objective. Evaluation of the relative amount of EVs and their coagulation activity using the thrombin generation test in CTEP and CTEPH patients. Design and methods. The study included 21 patients: the CTEP group (n = 7) and the CTEPH group (n = 14); and 11 healthy donors. EVs were isolated with the Exo-FACS kit and analyzed by flow cytometry using fluorescently labeled antibodies. The activity of the microparticles was assessed in a thrombin generation test using a trigger reagent without the addition of TF using a plate fluorimeter.</p></sec><sec><title>Results</title><p>Results. The relative content of EVs of platelet and endothelial origin was increased in CTEPH and CTEP groups. The level of platelet EVs correlates with the levels of CRP and D-dimer. LT and ttPeak were significantly increased in patients with CTEPH.</p></sec><sec><title>Conclusion</title><p>Conclusion. An increase in the level of platelet and endothelial EVs in patients with CTEPH and CTEP indicates the contribution of microvesiculation to the formation of post-thromboembolic syndrome. The activity of thrombin generation decrease under the action of TF-EVs could be a result of TF consumption in endothelial dysfunction, or prolonged activation of procoagulant pathways.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>внеклеточные везикулы</kwd><kwd>проточная цитометрия</kwd><kwd>тест генерации тромбина</kwd><kwd>тромбоэмболия легочной артерии</kwd><kwd>хроническая тромбоэмболическая болезнь</kwd><kwd>хроническая тромбоэмболическая легочная гипертензия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic thromboembolic pulmonary disease</kwd><kwd>chronic thromboembolic pulmonary hypertension</kwd><kwd>extracellular vesicles</kwd><kwd>flow cytometry</kwd><kwd>pulmonary embolism</kwd><kwd>thrombin generation test</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено за счет гранта Российского научного фонда № 22-25-20132, https:// rscf.ru/project/22-25-20132/</funding-statement><funding-statement xml:lang="en">The research was carried out at the expense of the grant of the Russian Science Foundation No. 22-25-20132, https://rscf.ru/ project/22-25-20132/</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lachant D, Bach C, Wilson B, et al. Clinical and imaging outcomes after intermediate — or high-risk pulmonary embolus. Pulm Circ. 2020; 10(3):2045894020952019. DOI: 10.1177/2045894020952019.</mixed-citation><mixed-citation xml:lang="en">Lachant D, Bach C, Wilson B, et al. Clinical and imaging outcomes after intermediate — or high-risk pulmonary embolus. Pulm Circ. 2020; 10(3):2045894020952019. DOI: 10.1177/2045894020952019.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Simonneau G, Torbicki A, Dorfmüller P, et al. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017; 26(143):160112. DOI: 10.1183/16000617.0112-2016.</mixed-citation><mixed-citation xml:lang="en">Simonneau G, Torbicki A, Dorfmüller P, et al. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017; 26(143):160112. DOI: 10.1183/16000617.0112-2016.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Pang W, Zhang Z, Wang Z, et al. Higher Incidence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism in Asians Than in Europeans: A Meta-Analysis. Front Med (Lausanne). 2021; 8:721294. DOI: 10.3389/fmed.2021.721294.</mixed-citation><mixed-citation xml:lang="en">Pang W, Zhang Z, Wang Z, et al. Higher Incidence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism in Asians Than in Europeans: A Meta-Analysis. Front Med (Lausanne). 2021; 8:721294. DOI: 10.3389/fmed.2021.721294.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Held M, Kolb P, Grün M, et al. Functional Characterization of Patients with Chronic Thromboembolic Disease. Respiration. 2016; 5091(6):503–9. DOI: 10.1159/000447247.</mixed-citation><mixed-citation xml:lang="en">Held M, Kolb P, Grün M, et al. Functional Characterization of Patients with Chronic Thromboembolic Disease. Respiration. 2016; 5091(6):503–9. DOI: 10.1159/000447247.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ramírez P, Otero R, Barberà JA. Pulmonary chronic thromboembolic disease. Arch Bronconeumol. 2020; 56(5):314–321. DOI: 10.1016/j.arbr.2020.03.007.</mixed-citation><mixed-citation xml:lang="en">Ramírez P, Otero R, Barberà JA. Pulmonary chronic thromboembolic disease. Arch Bronconeumol. 2020; 56(5):314–321. DOI: 10.1016/j.arbr.2020.03.007.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Konstantinides SV. Chronic thromboembolic disease following pulmonary embolism: more work ahead. Eur Respir J. 2020; 55(4):2000229. DOI: 10.1183/13993003.00229-2020.</mixed-citation><mixed-citation xml:lang="en">Konstantinides SV. Chronic thromboembolic disease following pulmonary embolism: more work ahead. Eur Respir J. 2020; 55(4):2000229. DOI: 10.1183/13993003.00229-2020.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021; 57(6):2002828. DOI: 10.1183/13993003.02828-2020.</mixed-citation><mixed-citation xml:lang="en">Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021; 57(6):2002828. DOI: 10.1183/13993003.02828-2020.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kato F, Tanabe N, Ishida K, et al. CoagulationFibrinolysis System and Postoperative Outcomes of Patients With Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016; 80(4):970–979. DOI: 10.1253/circj.CJ-15-1208.</mixed-citation><mixed-citation xml:lang="en">Kato F, Tanabe N, Ishida K, et al. CoagulationFibrinolysis System and Postoperative Outcomes of Patients With Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2016; 80(4):970–979. DOI: 10.1253/circj.CJ-15-1208.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Frey MK, Alias S, Winter MP, et al. Splenectomy is modifying the vascular remodeling of thrombosis. J Am Heart Assoc. 2014; 3(1):e000772. DOI: 10.1161/JAHA.113.000772.</mixed-citation><mixed-citation xml:lang="en">Frey MK, Alias S, Winter MP, et al. Splenectomy is modifying the vascular remodeling of thrombosis. J Am Heart Assoc. 2014; 3(1):e000772. DOI: 10.1161/JAHA.113.000772.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Khandagale A, Åberg M, Wikström G, et al. Role of Extracellular Vesicles in Pulmonary Arterial Hypertension: Modulation of Pulmonary Endothelial Function and Angiogenesis. Arterioscler Thromb Vasc Biol. 2020; 40(9):2293–2309. DOI: 10.1161/ATVBAHA.120.314152.</mixed-citation><mixed-citation xml:lang="en">Khandagale A, Åberg M, Wikström G, et al. Role of Extracellular Vesicles in Pulmonary Arterial Hypertension: Modulation of Pulmonary Endothelial Function and Angiogenesis. Arterioscler Thromb Vasc Biol. 2020; 40(9):2293–2309. DOI: 10.1161/ATVBAHA.120.314152.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mohan A, Agarwal S, Clauss M, et al. Extracellular vesicles: novel communicators in lung diseases. Respir Res. 2020; 21(1):175. DOI: 10.1186/s12931-020-01423-y.</mixed-citation><mixed-citation xml:lang="en">Mohan A, Agarwal S, Clauss M, et al. Extracellular vesicles: novel communicators in lung diseases. Respir Res. 2020; 21(1):175. DOI: 10.1186/s12931-020-01423-y.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Diehl P, Aleker M, Helbing T, et al. Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension. J Thromb Thrombolysis. 2011; 31(2):173–179. DOI: 10.1007/s11239-010-0507-z.</mixed-citation><mixed-citation xml:lang="en">Diehl P, Aleker M, Helbing T, et al. Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension. J Thromb Thrombolysis. 2011; 31(2):173–179. DOI: 10.1007/s11239-010-0507-z.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Alias S, Lang IM. Coagulation and the vessel wall in pulmonary embolism. Pulm Circ. 2013; 3(4):728–738. DOI: 10.1086/674768.</mixed-citation><mixed-citation xml:lang="en">Alias S, Lang IM. Coagulation and the vessel wall in pulmonary embolism. Pulm Circ. 2013; 3(4):728–738. DOI: 10.1086/674768.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bidot L, Jy W, Bidot C Jr, et al. Microparticlemediated thrombin generation assay: increased activity in patients with recurrent thrombosis. J Thromb Haemost. 2008; 6(6):913–919. DOI: 10.1111/j.1538-7836.2008.02963.x.</mixed-citation><mixed-citation xml:lang="en">Bidot L, Jy W, Bidot C Jr, et al. Microparticlemediated thrombin generation assay: increased activity in patients with recurrent thrombosis. J Thromb Haemost. 2008; 6(6):913–919. DOI: 10.1111/j.1538-7836.2008.02963.x.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37(1):67–119. DOI: 10.1093/eurheartj/ehv317.</mixed-citation><mixed-citation xml:lang="en">Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37(1):67–119. DOI: 10.1093/eurheartj/ehv317.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lacroix R, Judicone C, Mooberry M, et al. Standardization of pre-analytical variables in plasma microparticle determination: results of the international society on thrombosis and haemostasis SSC collaborative workshop. J Thromb Haemost. 2013; 2:10.1111/jth.12207.</mixed-citation><mixed-citation xml:lang="en">Lacroix R, Judicone C, Mooberry M, et al. Standardization of pre-analytical variables in plasma microparticle determination: results of the international society on thrombosis and haemostasis SSC collaborative workshop. J Thromb Haemost. 2013; 2:10.1111/jth.12207.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Melnichnikova O, Zhilenkova Y, Sirotkina O et al. Circulating Small Extracellular Vesicles Profiling and Thrombin Generation as Potential Markers of Thrombotic Risk in Glioma Patients. Front. Cardiovasc. Med. 2022; 9:789937.</mixed-citation><mixed-citation xml:lang="en">Melnichnikova O, Zhilenkova Y, Sirotkina O et al. Circulating Small Extracellular Vesicles Profiling and Thrombin Generation as Potential Markers of Thrombotic Risk in Glioma Patients. Front. Cardiovasc. Med. 2022; 9:789937.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33(1):4–15. DOI: 10.1159/000071636.</mixed-citation><mixed-citation xml:lang="en">Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33(1):4–15. DOI: 10.1159/000071636.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Guth S, D’Armini AM, Delcroix M, et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Res. 2021; 7(3):00850–2020. DOI: 10.1183/23120541.00850-2020.</mixed-citation><mixed-citation xml:lang="en">Guth S, D’Armini AM, Delcroix M, et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry. ERJ Open Res. 2021; 7(3):00850–2020. DOI: 10.1183/23120541.00850-2020.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Dodson MW, Sumner K, Carlsen J, et al. The Factor V Leiden variant and risk of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2020; 56(4):2000774. DOI: 10.1183/13993003.00774-2020.</mixed-citation><mixed-citation xml:lang="en">Dodson MW, Sumner K, Carlsen J, et al. The Factor V Leiden variant and risk of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2020; 56(4):2000774. DOI: 10.1183/13993003.00774-2020.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yang M, Deng C, Wu D, et al. The role of mononuclear cell tissue factor and inflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension. J Thromb Thrombolysis. 2016; 42(1):38–45. DOI: 10.1007/s11239-015-1323-2.</mixed-citation><mixed-citation xml:lang="en">Yang M, Deng C, Wu D, et al. The role of mononuclear cell tissue factor and inflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension. J Thromb Thrombolysis. 2016; 42(1):38–45. DOI: 10.1007/s11239-015-1323-2.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Skoro-Sajer N, Gerges C, Gerges M, et al. Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary hypertension-sampling plasma and surgical specimens. J Heart Lung Transplant. 2018; 37(9):1067–1074. DOI: 10.1016/j.healun.2018.04.003.</mixed-citation><mixed-citation xml:lang="en">Skoro-Sajer N, Gerges C, Gerges M, et al. Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary hypertension-sampling plasma and surgical specimens. J Heart Lung Transplant. 2018; 37(9):1067–1074. DOI: 10.1016/j.healun.2018.04.003.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma S, Lang IM. Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension. Thromb Res. 2018; 164:136–144. DOI: 10.1016/j.thromres.2017.06.011.</mixed-citation><mixed-citation xml:lang="en">Sharma S, Lang IM. Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension. Thromb Res. 2018; 164:136–144. DOI: 10.1016/j.thromres.2017.06.011.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е., Карабашева М.Б., Данилов Н.М. и др. Хроническая тромбоэмболическая легочная гипертензия: современный взгляд на проблему. Кардиологический вестник. 2019; 14(2):14–23. DOI: 10.17116/Cardiobulletin20191402114.</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Karabasheva MB, Danilov NM, et al. Chronic thromboembolic pulmonary hypertension: modern view on the problem. Russian Cardiology Bulletin. 2019; 14(2):14–23. In Russian DOI: 10.17116/Cardiobulletin20191402114.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Newnham M, South K, Bleda M, et al. The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019; 53(3):1801805. DOI: 10.1183/13993003.01805-2018.</mixed-citation><mixed-citation xml:lang="en">Newnham M, South K, Bleda M, et al. The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019; 53(3):1801805. DOI: 10.1183/13993003.01805-2018.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Banaszkiewicz M, Gąsecka A, Darocha S, et al. Circulating Blood-Based Biomarkers in Pulmonary Hypertension. J Clin Med. 2022; 11(2):383. DOI: 10.3390/jcm11020383.</mixed-citation><mixed-citation xml:lang="en">Banaszkiewicz M, Gąsecka A, Darocha S, et al. Circulating Blood-Based Biomarkers in Pulmonary Hypertension. J Clin Med. 2022; 11(2):383. DOI: 10.3390/jcm11020383.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Amabile N, Rautou PE, Tedgui A, et al. Microparticles: key protagonists in cardiovascular disorders. Semin Thromb Hemost. 2010; 36(8):907–916. DOI: 10.1055/s-0030-1267044.</mixed-citation><mixed-citation xml:lang="en">Amabile N, Rautou PE, Tedgui A, et al. Microparticles: key protagonists in cardiovascular disorders. Semin Thromb Hemost. 2010; 36(8):907–916. DOI: 10.1055/s-0030-1267044.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ohayon L, Zhang X, Dutta P. The role of extracellular vesicles in regulating local and systemic inflammation in cardiovascular disease. Pharmacol Res. 2021; 170:105692. DOI: 10.1016/j.phrs.2021.105692.</mixed-citation><mixed-citation xml:lang="en">Ohayon L, Zhang X, Dutta P. The role of extracellular vesicles in regulating local and systemic inflammation in cardiovascular disease. Pharmacol Res. 2021; 170:105692. DOI: 10.1016/j.phrs.2021.105692.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Amabile N, Heiss C, Real WM, et al. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med. 2008; 177(11):1268–1275. DOI: 10.1164/rccm.2007101458OC.</mixed-citation><mixed-citation xml:lang="en">Amabile N, Heiss C, Real WM, et al. Circulating endothelial microparticle levels predict hemodynamic severity of pulmonary hypertension. Am J Respir Crit Care Med. 2008; 177(11):1268–1275. DOI: 10.1164/rccm.2007101458OC.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Amabile N, Heiss C, Chang V, et al. Increased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients. J Heart Lung Transplant. 2009; 28(10):1081–1086. DOI: 10.1016/j.healun.2009.06.005.</mixed-citation><mixed-citation xml:lang="en">Amabile N, Heiss C, Chang V, et al. Increased CD62e(+) endothelial microparticle levels predict poor outcome in pulmonary hypertension patients. J Heart Lung Transplant. 2009; 28(10):1081–1086. DOI: 10.1016/j.healun.2009.06.005.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Gasa N, Meiring M. Microparticles: a link to increased thrombin generation. Blood Coagul Fibrinolysis. 2021; 32(3):204–208. DOI: 10.1097/MBC.0000000000001018.</mixed-citation><mixed-citation xml:lang="en">Gasa N, Meiring M. Microparticles: a link to increased thrombin generation. Blood Coagul Fibrinolysis. 2021; 32(3):204–208. DOI: 10.1097/MBC.0000000000001018.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Melnichnikova O, Simakova M, Moiseeva O, et al. The dynamics of thrombin formation in patients with pulmonary arterial hypertension. Thromb Res. 2021; 208:230–232. DOI: 10.1016/j.thromres.2021.07.015.</mixed-citation><mixed-citation xml:lang="en">Melnichnikova O, Simakova M, Moiseeva O, et al. The dynamics of thrombin formation in patients with pulmonary arterial hypertension. Thromb Res. 2021; 208:230–232. DOI: 10.1016/j.thromres.2021.07.015.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Vrigkou E, Tsangaris I, Bonovas S, et al. Platelet and coagulation disorders in newly diagnosed patients with pulmonary arterial hypertension. Platelets. 2019; 30(5):646–651. DOI: 10.1080/09537104.2018.1499890.</mixed-citation><mixed-citation xml:lang="en">Vrigkou E, Tsangaris I, Bonovas S, et al. Platelet and coagulation disorders in newly diagnosed patients with pulmonary arterial hypertension. Platelets. 2019; 30(5):646–651. DOI: 10.1080/09537104.2018.1499890.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
